25-OHCC - 25-hydroxycholecalciferol
RxNorm 1889
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1889 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: 25-OHCC - 25-hydroxycholecalciferol.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SYPrescribable
Synonym (SY):
25-HCC - 25-hydroxycholecalciferol
(Atom ID: 10293033)
SYPrescribable
Synonym (SY):
25-hydroxycholecalciferol
(Atom ID: 10293035)
SYPrescribable
Synonym (SY):
25-hydroxyvitamin D3
(Atom ID: 10293036)
SYPrescribable
Synonym (SY):
25-OHCC - 25-hydroxycholecalciferol
(Atom ID: 10293034)
INPrescribable
Ingredient (IN):
Calcifediol
(Atom ID: 12250434)
PTPrescribable
Designated preferred name (PT):
Calcifediol
(Atom ID: 10295326)
FNPrescribable
Full form of descriptor (FN):
Calcifediol (substance)
(Atom ID: 10295327)
PTPrescribable
Designated preferred name (PT):
Calcifediol-containing product
(Atom ID: 10798664)
FNPrescribable
Full form of descriptor (FN):
Product containing calcifediol (medicinal product)
(Atom ID: 9723644)
Patient Education
Calcifediol
Calcifediol is used to treat secondary hyperparathyroidism (a condition in which the body produces too much parathyroid hormone [PTH; a natural substance needed to control the amount of calcium in the blood], ) in certain adults with chronic kidney disease (condition in which the kidneys stop working slowly and gradually). Calcifediol is in a class of medications called vitamin D analogs. It works by helping the body to use more of the calcium found in foods or supplements and by regulating the body's production of parathyroid hormone.
[Learn More]
* Please review the disclaimer below.